Medeon Biodesign Market Cap ($226.02 Million)
Market Cap & Net Worth: Medeon Biodesign (6499)
Medeon Biodesign market cap. Medeon Biodesign (TWO:6499) has a market capitalization of $226.02 Million (NT$7.17 Billion) as of November 1, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #15884 globally and #735 in its home market, demonstrating a -11.59% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Medeon Biodesign's stock price NT$74.00 by its total outstanding shares 96944893 (96.94 Million). Also see 6499 cash flow conversion for how efficiently the company converts equity into cash flow.
Medeon Biodesign Market Cap History (2015–2026)
Medeon Biodesign market cap history from 2015 to 2026. Data shows change from $528.20 Million to $226.02 Million (-6.39% CAGR). Check Medeon Biodesign share price for real-time trading data and today's change.
Medeon Biodesign Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Medeon Biodesign's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore how fast is Medeon Biodesign growing its equity to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.69x
Medeon Biodesign's market cap is 0.69 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $161.96 Million | $164.77 Million | -$247.52 Million | 0.98x | N/A |
| 2018 | $173.38 Million | $673.53 Million | $256.60 Million | 0.26x | 0.68x |
| 2019 | $135.57 Million | $453.76 Million | -$261.99 Million | 0.30x | N/A |
| 2020 | $118.19 Million | $653.90 Million | -$192.74 Million | 0.18x | N/A |
| 2021 | $213.31 Million | $68.96 Million | $2.08 Billion | 3.09x | 0.10x |
| 2022 | $167.27 Million | $298.32 Million | -$433.76 Million | 0.56x | N/A |
| 2023 | $142.48 Million | $196.26 Million | -$1.20 Billion | 0.73x | N/A |
| 2024 | $121.10 Million | $292.81 Million | -$805.51 Million | 0.41x | N/A |
| 2025 | $288.63 Million | $419.43 Million | -$668.06 Million | 0.69x | N/A |
Competitor Companies of 6499 by Market Capitalization
Companies near Medeon Biodesign in the global market cap rankings as of November 1, 2026. Also see Medeon Biodesign (6499) total assets for a full breakdown of the balance sheet.
Key companies related to Medeon Biodesign by market ranking:
- Intuitive Surgical Inc (NASDAQ:ISRG): Ranked #175 globally with a market cap of $132.26 Billion USD.
- EssilorLuxottica S. A. (PA:EL): Ranked #258 globally with a market cap of $99.77 Billion USD ( €85.34 Billion EUR).
- ESSILORLUXOTTICA 1/2/O.N. (F:ESLC): Ranked #421 globally with a market cap of $67.43 Billion USD ( €57.68 Billion EUR).
- HOYA CORP. ADR/ 1 O.N. (F:HYB0): Ranked #536 globally with a market cap of $50.37 Billion USD ( €43.09 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #175 | Intuitive Surgical Inc | NASDAQ:ISRG | $132.26 Billion | $432.01 |
| #258 | EssilorLuxottica S. A. | PA:EL | $99.77 Billion | €184.30 |
| #421 | ESSILORLUXOTTICA 1/2/O.N. | F:ESLC | $67.43 Billion | €87.50 |
| #536 | HOYA CORP. ADR/ 1 O.N. | F:HYB0 | $50.37 Billion | €150.00 |
Market Capitalization of Medeon Biodesign (2015–2026)
Market capitalization of Medeon Biodesign from 2015 to today. Between 2015 and today, Medeon Biodesign's market cap moved from $528.20 Million to $ 226.02 Million, with a yearly change of -6.39%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$226.02 Million | -21.69% |
| 2025 | NT$288.63 Million | +138.34% |
| 2024 | NT$121.10 Million | -15.01% |
| 2023 | NT$142.48 Million | -14.82% |
| 2022 | NT$167.27 Million | -21.58% |
| 2021 | NT$213.31 Million | +80.47% |
| 2020 | NT$118.19 Million | -12.82% |
| 2019 | NT$135.57 Million | -21.81% |
| 2018 | NT$173.38 Million | +7.05% |
| 2017 | NT$161.96 Million | -42.48% |
| 2016 | NT$281.58 Million | -46.69% |
| 2015 | NT$528.20 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Medeon Biodesign was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $226.02 Million USD |
| MoneyControl | $226.02 Million USD |
| MarketWatch | $226.02 Million USD |
| marketcap.company | $226.02 Million USD |
| Reuters | $226.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Medeon Biodesign
Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular g… Read more